Copyright ©The Author(s) 2018.
World J Gastroenterol. May 14, 2018; 24(18): 1925-1941
Published online May 14, 2018. doi: 10.3748/wjg.v24.i18.1925
Table 1 Tyrosine kinase inhibitor election based on genes mutations
GeneMutationTKI. Dose
KITExon 11Imatinib-Mesylate 400 mg/d
Exon 13
Exon 17
Exon 9Imatinib-Mesylate 800 mg/d
PDGFRAExon 18. D842V mutationSunitinib 50 mg/d
Regorafenib 160 mg/d
Exon 12Imatinib-Mesylate 400 mg/d
Exon 14
Exon 18. Non D842V mutations.
Wild-typeSunitinib 50 mg/d
Regorafenib 160 mg/d
Table 2 Risk stratification criteria for primary resectable gastrointestinal stromal tumor porposed by Joensuu
Risk categoryTumour size (cm)Mitotic index (per 50 HPF)Primary tumour site
Very low risk≤ 2.0≤ 5Any
Low risk2.1-5.0≤ 5Any
Intermediate risk≤ 5.06-10Gastric
5.1-10.0≤ 5Gastric
High riskAnyAnyTumour rupture
> 10.0AnyAny
Any> 10Any
> 5.0> 5Any
≤ 5.0> 5Non-gastric
5.1-10.0≤ 5Non-gastric
Table 3 Items that pathology report should include
Pathology report items
Number of foci
Tumor infiltration
Histologic subtype
Depth of tumor infiltration
Grade of dedifferentation
Mitotic rate
Grade of necrosis
Grade of hemorrhage
Mutational study